Emmaus Life Sciences Inc
Change company Symbol lookup
Select an option...
EMMA Emmaus Life Sciences Inc
NOBL ProShares S&P 500 Dividend Aristocrats ETF
NLY Annaly Capital Management Inc
NGG National Grid PLC
NEM Newmont Corporation
NDP Tortoise Energy Independence Fund, Inc
NCV AllianzGI Convertible & Income Fund
NCV AllianzGI Convertible & Income Fund
NAC Nuveen California Quality Municipal Income Fund
MUC BlackRock MuniHoldings California Quality Fund, Inc.
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Emmaus Life Sciences, Inc., formerly MYnd Analytics, Inc., is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing and sale of treatments and therapies for rare and orphan disease categories. The Company provides ENDARI, which is an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Closing Price
$1.29
Day's Change
0.09 (7.50%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.33
Day's Low
1.10
Volume
(Below Average)
Volume:
30,435

10-day average volume:
35,240
30,435

Company Profile

Emmaus Life Sciences, Inc., formerly MYnd Analytics, Inc., is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing and sale of treatments and therapies for rare and orphan disease categories. The Company provides ENDARI, which is an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
11.15x
Price/Book (MRQ)
--
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

No short interest available.

Share Information

EMMA is in a share class of common stock
Float
50.6M
Shares Outstanding
64.5M
Institutions Holding Shares
1
0.49%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Yutaka NiiharaChmn.
  • Lan T. TranPres.
  • Willis C. LeeVice Chmn.
  • Joseph Charles SherwoodCFO
  • Yasushi Nagasaki

Address

Insider Trading

During the most recent quarter, 341K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.